Thank Elite Robert pipeline, comments products. commercial a financials echoing you, Today’s then few include and development Robert. told about safety what and update us just will cover research
and Before lot opioid buildings, we of force. in go about will partner are and the marketing of potential interested to of also talk The new Q&A, I strategy. that a sales purchase people
providers a marketing affecting partners. the pandemic It suppliers, else’s all. in as business our Regarding we well sales It in a once safety, as in is operating is and affecting business, and life States is and that globally. us Elite, COVID-XX our service is are pandemic. United a everyone affecting
and and are of the local following vaccinated. We guidelines, CDC’s Most continue our recommendations. federal employees
been materially shipping any To-date We us continuity. importantly, the impacted. the a on are for our to been easy. taking chain say have My not takes not pandemic the problems. frankly. supply to precautions ensure continue. we to still halt the chain our not have regarding missing and and inflation all component it business the of and not That effects and It bring has is been in products United safety, by other commercial manufacturing affected and States industry lives necessary is to one concern most employee supply All businesses
in say in trials. our are on the R&D the will mostly I feeling that about form of delays clinical pipeline We more impact later.
sales not and our Regarding and revenues, and going, money I flow. hope on very partners this are Two and the working years all enough hit direction we Today, have profits for profitable. are the sales profits, did pleased numbers, we self-sufficient capital. on and path. revenues Robert marketing cash ago, right with am the continue
just solid what to $XX said, in We $XX this four we years went $X.X surpassed is million and to million we have million in to year’s from performance, year, last excellent hit revenues revenues million. progress. in That revenues Robert $XX echo and
there I said, lot of were questions As about building. the a
So worked all department that’s was offer it. manufacturing, much the sell the to decided XXX, He to of amazing our manufacturing the We young the any an of kind building. XX-year the our to us still for has with to but a man I beginning not was that us of on owner the am enough years. street. houses had with who that pretty year, packaging, We from building. He the company He renew going lease, offer buy warehouse, got Around XXX, buildings start the Building the and that. quality four buying could after assurance on that. facility years is more update
So we went a market the of around looked us. and at our quick analysis options through
into First, place. area The we would and out extended is facilities. another happen move and evaluated group that’s the buying we long-term it if nursing homes what converting rent
to have rent warehouse will moved we we a buildings, if out, similar building. rent So we the if
not the were prices the twice being almost checking XX-year retired gentleman a Florida gotten Apparently First, wonderful prices has have on old XX%. and been of we a discount rental the much. as in
Second, that equipments are loss. anytime certain you will a be there move, total
walls million, that For example, $X to electronics installation, we in almost has bed it’s that mostly and cost the in out fluid us moved. and embedded have be a the and taken
products tech that or of all the clinical the for there’s cost you of transfer have. Third, trials
It on. run you cost us have submit $X than the FDA more $X to at to have It the the new so and equipment us cost building. to out, the to you get to them million you more later the So about there calculate batches actually of end will kidding. price cost buy will to approval in when move your to addition, order day, can than of stay. No million you move if new in
our the analysis building Board would action sometime are alternative So we We a to best been move try The in and This was it with much the positive that step and I instructed went for was to Directors happy closing forward July. Board more say to to January have the a costly. buy Elite. in am very very us of no the brainer. and
for actually We premium. that them sold have that lease final the the we asset condition they in to part like California. thing. at on a us we company a We manufacturing that, anytime a that when you building addition, positive a the found comments before In buyer been it company of the had the money. I own this, it’s we needed under had an back
have we in the once also we of So to it pay about now is way not in the Right bad for other equity. finance it built and cash raise half. future half a
lot rent than are per the payments Our less now were before. That they less than a is is lot mortgage. a what month the
R&D, amount the development continues research is number to and on one Elite one number of priority and development. our research focus. and It spend Regarding significant
Amphetamine that enough are to get diverse that such they is create case stabilize in hit such better for to suffer are a that company products we survive. all as material not IR the company, of or goal us. on is and we more one ER, at add Our of to materially can stabilize company can least The new will products us the and two set that the pillars the it
are the Generic of a and to number India. on There As three time things approval to take are the these different that you ANDA apply Elite by of they other we will trials trials. that well. received done affected know, average for execute products clinical contract Currently, U.S. licenses. clinical working protect longer One three trials Sabril. have the we for. the import/export the COVID. Two to an we and that patients, have two one The as got regulations in are is signed be difficult of clinical the than in generics
clinical this we had the products the have company Again, instead one So the has trials for even really results would on us. impact by I hoping can started only that now some the of have has atmosphere process. the you of CROs not today’s slower things opportunities is are our this, that The we work than moving and bottomline currently within this we with usual have that. that many to atmosphere, operate being are pursued. have from is you and was
by the all trials. well-developed at One have tablet, Doxycycline for and that are range we a year to Elite. early This approvals XXXX total received SunGen/Praxgen with that We from product -- we the other we is of are have owned FDA. co-own level Generic R&D and that the way ANDA ANDAs is Sabril, from XX have clinical development two a six which
an Lannett marketing with and our thoughts determine to want be it. own their will really working to need the we agreement and forward with work the on months licensed step. few partner to them to implement. figure to we we with the have almost to with This all is Praxgen/SunGen it. it next to next we that to Lannett over you order that and pharmacist, They in and this been to specialized product need have in to of REMS negotiate do. will a out take want year a the handle work sales they Doxy, how has out are ago. that. includes is educated Lannett how order with product patient This Sabril, take physician And to Genetic move going component Regarding
the that or are are rest Amphetamine of market. products IR the products, commercial very Regarding in ER a two competitive
We us, very Lannett well have have very well. for They of done and done Elite. both
with that doing. job the is We Lannett are happy
Lannett before, ER Amphetamine stated the has an this for for and As for approval IR. approval waiting
and official agreements an Lannett for received distribution this not have We from the terminate to sales product. notice wishing
background sales evaluating that we do are do as To happen its because notice case need in me other ourselves, fingerprinting things things and the That’s and we has they to get if necessary because we get are lot are it marketing end, officially cannot requirements, partner wait a all happens, this can advance. state to, we We way and it we XX ourselves. protect need if from the six each $XXX,XXX that is and license just you a to taking are licensed bond, measures whether we to of works. send till do all in all FBI one there such a we you states. in to state So still to or the evaluating of of our check going are Elite be from months receive it that takes them, states minimum and own in licensed when ranging and if partner. But are need checks,
applications. So XX far, about we filed state
within two rest months. expect be done will the We the next
for want do interviewing somebody center. product to need have also distribution for need third-party to start third-party the either who we and and three distribution our pricing. own order evaluating us We distribution we comparing launch the a are ourselves companies, logistics PL whether In or logistics we to
in the are it sales the just about own. really decide said once of that. more on we too forward all marketing. their This complex ANDAs. high for us So not we talking sales Loxapine, finally, I and to of is the one Elite. they feeling are planning accelerate that, be amount a may to is potential that’s case it our effect Sales last stakes market own for out get going four require the stay all for and chain. Marketing emphasize, looking me always wanted and to it. at may we to was but process. Enough Again, VPs and June nothing, Lannett, and to team President I able launched to and ready said And by to let Vice are affected be the this of products the was that that have Having interviewing on a both. operation marketing move cost we or handle it we for Having may something as is with supply
Prasco, brand their bids to components couldn’t partner, supply. small take you of because one that get were a going that marketed in with and Our product was make short business who Burel under to the we
failure in up double have will So because supply. and we deliver to pay the could not business to or a we end not could then we where to we triple promise problem for
I that. chain So do well we they supply it doing are They resolve now the working once better we through with are hope will and issue.
are this products in our Trimipramine, Isradipine seeing these continues. revenues expect that. that. six and I is Epic within issues limited next we partner these competition. and about and hopefully, growth a with profit interesting always Epic, NASDAQ. resolve to or products. have from little are months product, future expect They about are so. and we the more hope With questions that They There asked many get We
when time thing will right, not is When the for are the again. time uplist everybody we first say NASDAQ. So the and to that I before there NASDAQ second meet the qualify Elite for is have must but many same specific key part, goal the remember the A times requirements the to right, part, discussed is uplisting. Elite
working to achieve diligently them. We are
$X.X $XX we that, are not but million revenue there is Going in from of yet. part million a to
that their it investment, going us it’s that lucrative would And right NASDAQ back the in of the we you the it to will have it happens to generation going the is growth lot if we to fundamentals. and why have. have We we everybody risk the is reversal whether time if NASDAQ thing to fundamentals do you my split the it period on or Because monitor for and This we have when and fine. will be the tomorrow unless through even And of not would for we going sound Board, continue could am is companies gravitate to a fundamentals of of our years okay. and though when it’s I update voice to happen not income for It will bulletin gravitating short to get a and at XX, board. and the XXX then a get to and on uplisting XX not fine. easily. OTC we it’s going very right we to don’t XX happens, XX-fold happens is happens, what right. I and do time the in right us it through company get whatever the and years there, back NASDAQ lose resisted any
product approvals and product Okay, plans, Elite capitalizing on on on is up, this executing to growth commercial its new lines. working wrap its
well. profitable year. another and are to performing distribution forward We sales partners Our look
are Many others of Dianne family. of you them and have within the are always, repeat sent whole a As same questions. bunch
into she will So divided and try to next. address them categories those we
on Before I have me if I And the a an any question have is we email passed them since start, asking other building. already no. I with on a late Dianne sent mentioned about the update gentleman Pfizer with the answer that to given communications before?
So I question repeat address other three of. care potential If have that is that’s these partners. not, already not am I our tangential Lannett If going with partnership it. and there taken will a to been again or
